Medscape5h
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Hosted on MSN3d
FDA Expands Approval of Esketamine for Depression
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
Hosted on MSN3h
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The American Journal of Managed Care3d
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
Daily2d
FDA Approves Esketamine Nasal Spray for Treatment-Resistant Depression
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
WLRN2d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...
IFLScience1d
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
HealthDay on MSN1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
pharmaphorum3d
FDA approves Janssen’s ketamine-based nasal antidepressant
It is now approved for adults with treatment-resistant depression (TRD) who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster ...
pharmaphorum1d
Compass plans $100m IPO to fund magic mushroom depression drug
By targeting treatment-resistant depression, COMP360 will come into competition with Johnson & Johnson’s Spravato (esketamine) and a combination of olanzapine and fluoxetine if approved.
Putnam Daily Voice3d
Nasal Spray Treating Major Depression Receives FDA Approval For Standalone Use
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...